SCHEMBL2209649

SCHEMBL2209649

COc1cc(OC)c(C=CS(=O)(=O)Nc2ccc(OC)c(NC(=O)c3cc(N)cc(N)c3)c2)c(OC)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
MAPK1 P28482 2/20 0.46
MAPT P10636 5/20 0.44
PLK1 P53350 4/20 0.44
HDAC1 Q13547 3/20 0.44
HDAC8 Q9BY41 3/20 0.44
HDAC6 Q9UBN7 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HTT P42858 2/20 0.44
HDAC3 O15379 2/20 0.44
HDAC4 P56524 2/20 0.44
HDAC7 Q8WUI4 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC9 Q9UKV0 2/20 0.44
HDAC5 Q9UQL6 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2210376 1.00 TSHR (0.46) TSHRMAPK1MAPTPLK1HDAC1
SCHEMBL2213353 0.92 MAPT (0.49) TSHRMAPK1MAPTPLK1HDAC1
SCHEMBL2212729 0.92 MAPT (0.49) TSHRMAPK1MAPTPLK1HDAC1
SCHEMBL2210509 0.88 KMT2A (0.53) TSHRMAPK1MAPTPLK1HDAC1
SCHEMBL2210459 0.88 KMT2A (0.53) TSHRMAPK1MAPTPLK1HDAC1
SCHEMBL2213252 0.86 PLK1 (0.48) MAPK1MAPTPLK1HDAC1HDAC8
SCHEMBL2213268 0.86 PLK1 (0.48) MAPK1MAPTPLK1HDAC1HDAC8
SCHEMBL2212176 0.85 MEN1 (0.54) TSHRMAPK1MAPTPLK1HDAC1
SCHEMBL2212169 0.85 MEN1 (0.54) TSHRMAPK1MAPTPLK1HDAC1
SCHEMBL2210303 0.84 PLK1 (0.49) MAPK1MAPTPLK1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534284-B1 AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2011-07-27 EP claimed
EP-1534284-B1 AMINO-SUBSTITUTED SULFONANILIDES AND DERIVATIVES THEREOF FOR TREATING PROLIFERATIVE DISORDERS UNIV TEMPLE (US) 2011-07-27 EP disclosed
US-7161031-B2 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-01-09 US disclosed
US-20050096484-A1 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders ONCONOVA THERAPEUTICS, INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096484-A1 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders ARSA, MKI67, CCNA1 TSHR 795/4885MAPK1 1489/4885MAPT 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.